English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Dear Sir, The cloning of the islet cell autoantigen 69 (ICA69) has raised expectations for an additional marker for the prediction of insulin-dependent diabetes mellitus (IDDM) [1, 2]. However, a recent report suggests that ICA69 autoantibodies appear also in rheumatoid arthritis and only in a subgroup of IDDM patients [3], and another group did not show any significant elevation of ICA69 autoantibodies in IDDM [4]. We therefore conducted an exchange of coded sera. Three Western blot assays of recombinant ICA69 and one immunoprecipitation assay of in vitro translated recombinant protein were included. A total of 89 lyophilized sera used in the second glutamic acid decarboxylase antibody workshop were kindly provided by Dr. E Colman (Royal Melbourne Hospital, Victoria, Australia). An ICA69 antibody standard was not employed and the local laboratories used different approaches to define the cutoff level for antibody positivity. The results showed substantial interassay variations. Only one assay showed a significantly elevated percentage of IDDM patients positive for ICA69

Islet cell autoantigen 69 antibodies in IDDM